Galapagos NV (GLPG)
- Previous Close
29.76 - Open
29.32 - Bid 29.16 x 200
- Ask 29.32 x 200
- Day's Range
29.24 - 29.49 - 52 Week Range
24.16 - 42.46 - Volume
23,816 - Avg. Volume
146,201 - Market Cap (intraday)
1.93B - Beta (5Y Monthly) 0.07
- PE Ratio (TTM)
54.24 - EPS (TTM)
0.54 - Earnings Date Oct 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
32.64
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
www.glpg.comRecent News: GLPG
View MorePerformance Overview: GLPG
Trailing total returns as of 8/30/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GLPG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GLPG
View MoreValuation Measures
Market Cap
1.97B
Enterprise Value
-1.84B
Trailing P/E
55.47
Forward P/E
166.67
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.70
Price/Book (mrq)
0.60
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
108.11%
Return on Assets (ttm)
-1.76%
Return on Equity (ttm)
1.15%
Revenue (ttm)
261.4M
Net Income Avi to Common (ttm)
31.5M
Diluted EPS (ttm)
0.54
Balance Sheet and Cash Flow
Total Cash (mrq)
3.43B
Total Debt/Equity (mrq)
0.37%
Levered Free Cash Flow (ttm)
-292.63M